智通财经网·2026-01-06 01:37Group 1 - The core viewpoint is that JD Health's revenue forecasts for 2025 and 2026 have been raised by 2% to 72.5 billion and 81.7 billion respectively, driven by the strong demand for flu products and the ongoing trend of original research products [1] - The company is expected to achieve a year-on-year revenue growth of approximately 25% in 2025, with strong quarterly performance observed in the first three quarters [2] - The non-IFRS net profit for 2025 and 2026 has been adjusted upwards by 4% and 1% to 6.5 billion and 6.4 billion respectively, with a new revenue forecast for 2027 set at 91.2 billion and non-IFRS net profit at 6.8 billion [1] Group 2 - The company has shown a steady improvement in non-IFRS net profit margins, with rates of 10.6%, 9.7%, and 11.1% in the first three quarters of 2025, attributed to increased marketing investments by pharmaceutical and health product companies [3] - Despite the potential fluctuations in interest income due to cash management strategies, the overall profit performance is expected to remain robust, reflecting the company's strong competitive position [3] - The company has signed strategic cooperation agreements with major pharmaceutical firms, enhancing its business model for new drug launches [2]